Kiwi, The entire history of Vascepa can be summed up in
a warning that some poster had written long, long ago. That is,
when a small inept bio decides to GIA they end up "having a great
drug being laid to waste." Whenever i would bring up the necessity
for a BP BO there were always posters who stated that Vascepa
would sell itself. I still hold up hope that this situation will be salvaged
in some way. I do wonder what Dr. Bhatt must think about the situation
and what his solution would be. Kiwi, from your example one point
that stands out is how well NVS is doing with its product in China.
Too bad that AMRN management decided to partner with Edding
which was done because of a BOD connection. Edding seems
to have done little in producing significant sales in China. Pathetic!
Market Data 
Markets 
AI
